Effects of canagliflozin on cardiovascular and kidney outcomes and mortality in primary and secondary cardiovascular prevention: pooled analysis from the CANVAS program and CREDENCE trial

Abstract Background/Introduction Individuals with type 2 diabetes mellitus (T2DM) are at a greater risk for experiencing cardiovascular (CV) and kidney events. Canagliflozin is sodium glucose co-transporter inhibitor that has demonstrated reduction of these events in participants T2DM or without history CV disease (CVD) both the CANVAS Program CREDENCE trial. Purpose To determine pooled effects canagliflozin on outcomes, all-cause mortality trial CVD (secondary primary prevention, respectively). Methods This post hoc analysis individual participant data from The versus placebo time to first event outcomes (major adverse [MACE], which was defined as death, myocardial infarction [MI] stroke; death; hospitalization heart failure [HHF], composite death HHF), (end-stage [ESKD], doubling serum creatinine [dSCr], ESKD dSCr), were assessed CVD. Results Among 14,543 (N=10,142) (N=4401), 5667 (39%; canagliflozin, n=3128; placebo, n=2539) prevention group 8876 (61%; n=4869; n=4007) secondary group. Baseline characteristics each generally similar. Across participants, no heterogeneity relative observed (all P interaction >0.624; Figures 1 2). benefits MACE HHF early 6 months into treatment subgroups sustained throughout study. Conclusions In this patient-level trial, associated reduced mortality, similar results across T2DM. Funding Acknowledgement Type funding sources: Private company. Main source(s): Janssen, Inc.